Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company reported sales of $627.7 million compared to $515.
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Down 18.53%
Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time to buy.
Q4 2024 Neurocrine Biosciences Inc Earnings Call
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/104.D7q0jHs_.js
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock a buy.
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Neurocrine Biosciences stock falls on revenue miss
Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® (valbenazine) net product sales for the full year of 2024 compared to the previous year, the company's guidance for 2025 disappointed investors.
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer
Neurocrine Biosciences Inc Q4 Profit Decreases, Misses Estimates
Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.44 per share a year ago. These figures are adjusted for non-recurring items.
These Stocks Are Moving the Most Today: Amazon, Affirm, Pinterest, Take-Two, Bill Holdings, e.l.f. Beauty, Neurocrine Biosciences, and More
Amazon falls after guidance disappoints and cloud-computing growth misses estimates, Affirm jumps after fiscal second-quarter ...
Neurocrine price target lowered to $185 from $190 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.
Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...
Neurocrine price target lowered to $147 from $157 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...
Hosted on MSN1d
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.